Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure
- PMID: 3707648
Evaluation of acute hemodynamic effects and pharmacokinetic behaviour of ibopamine in patients with severe heart failure
Abstract
The aim of the present investigation was to evaluate the acute hemodynamic effects of a single oral dose of 200 mg ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine (epinine) in 11 patients with congestive heart failure (CHF) and to compare the influence of dopamine infusion and oral ibopamine on left ventricular function. Free and conjugated epinine plasma levels were also investigated in these patients and in a group of healthy volunteers to evaluate the correlation between epinine plasma levels and hemodynamic effects. The oral administration of 200 mg ibopamine to patients with CHF, increased cardiac index (+35%) and reduced peripheral and pulmonary vascular resistance (-29% and -26%) without modifying heart rate and systemic or pulmonary arterial pressure. The hemodynamic effect reached its maximum at about 90 min and was still present at 240 min. Ibopamine at a dose of 200 mg elicited similar effects to those observed with dopamine, 2-4 micrograms/kg/min. The pharmacokinetic behaviour of ibopamine in these patients was similar to that observed in a group of healthy volunteers. Free epinine plasma levels peaked at 30-60 min and decreased rapidly, thus showing a shorter time course than the hemodynamic effects.
Similar articles
-
Hemodynamic evaluation during exercise test after acute and chronic ibopamine treatment in patients with congestive heart failure.Arzneimittelforschung. 1986 Feb;36(2A):366-70. Arzneimittelforschung. 1986. PMID: 3707652
-
Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure.Arzneimittelforschung. 1986 Feb;36(2A):355-9. Arzneimittelforschung. 1986. PMID: 3707649 Clinical Trial.
-
Efficacy of ibopamine treatment in patients with advanced heart failure: purpose of a new therapeutic scheme with multiple daily administrations.J Cardiovasc Pharmacol. 1989;14 Suppl 8:S111-7. J Cardiovasc Pharmacol. 1989. PMID: 2483436
-
[Ibopamine--pharmacologic principles].Z Kardiol. 1991;80 Suppl 8:63-6. Z Kardiol. 1991. PMID: 1686693 Review. German.
-
Ibopamine--how should it be used?Cardiology. 1988;75 Suppl 1:126-37. doi: 10.1159/000174452. Cardiology. 1988. PMID: 3069210 Review.
Cited by
-
The pharmacokinetics and pharmacodynamics of newer inotropic agents.Clin Pharmacokinet. 1987 Aug;13(2):91-109. doi: 10.2165/00003088-198713020-00002. Clin Pharmacokinet. 1987. PMID: 3304772 Review.
-
Acute effect of ibopamine and isosorbide mononitrate on blood volume distribution in congestive heart failure.Eur J Clin Pharmacol. 1994;47(4):325-30. doi: 10.1007/BF00191163. Eur J Clin Pharmacol. 1994. PMID: 7875183 Clinical Trial.
-
Ibopamine. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.Drugs. 1988 Jul;36(1):11-31. doi: 10.2165/00003495-198836010-00003. Drugs. 1988. PMID: 3063492 Review.
-
Peripheral hemodynamic effects of ibopamine in patients with congestive heart failure. A placebo-controlled, double-blind study.Cardiovasc Drugs Ther. 1989 Apr;3(2):199-202. doi: 10.1007/BF01883865. Cardiovasc Drugs Ther. 1989. PMID: 2487532 Clinical Trial.
-
Ibopamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in congestive heart failure.Drugs Aging. 1993 Nov-Dec;3(6):556-84. doi: 10.2165/00002512-199303060-00008. Drugs Aging. 1993. PMID: 7906158 Review.
MeSH terms
Substances
LinkOut - more resources
Medical